Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
about
Genome-wide association with select biomarker traits in the Framingham Heart StudyN-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart diseaseMyocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesisAssessing Risk in Patients with Stable Coronary Disease: When Should We Intensify Care and Follow-Up? Results from a Meta-Analysis of Observational Studies of the COURAGE and FAME EraNatriuretic Peptides and Cardiometabolic Health2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Atrial natriuretic peptide in cardiovascular biology and disease (NPPA)INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologistUncoordinated regulation of atrial natriuretic factor and brain natriuretic peptide in lipopolysaccharide-treated ratsSelf-reported symptoms of chronic cough and breathlessness in working-age men in the city of Izhevsk, Russia: associations with cardiovascular disease risk factors and comorbiditiesHigh-sensitivity cardiac troponin T: risk stratification tool in patients with symptoms of chest discomfortLmod2 piggyBac mutant mice exhibit dilated cardiomyopathy.Investigating Prevalence and Pattern of Long-term Cardiovascular Disorders in Sulphur Mustard-exposed Victims and Determining Proper Biomarkers for Early Defining, Monitoring and Analysis of Patients' Feedback on Therapy.Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.Reduced fractional shortening of right ventricular outflow tract is associated with adverse outcomes in patients with left ventricular dysfunction.Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases.Analysis of transthoracic echocardiographic data in major vascular surgery from a prospective randomised trial comparing sevoflurane and fentanyl with propofol and remifentanil anaesthesia.Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial.Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis.Plasma brain natriuretic peptide as a surrogate marker for cardioembolic strokeTroponin T, NT-proBNP, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE).Galectin 3 and incident atrial fibrillation in the community.Natriuretic Peptide testing in primary careManifold implications of obesity in ischemic heart disease among Japanese patients according to covariance structure analysis: Low reactivity of B-type natriuretic peptide as an intervening risk factor.Insulin resistance is associated with increased concentrations of NT-proBNP in rheumatoid arthritis: IL-6 as a potential mediatorThe influence of pericardial fat upon left ventricular function in obese females: evidence of a site-specific effect.Cardiac Natriuretic Peptides, Hypertension and Cardiovascular RiskDynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing.NT-proBNP and circulating inflammation markers in prediction of a normal myocardial scintigraphy in patients with symptoms of coronary artery disease.Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative.Plasma NT-proBNP as predictor of change in functional status, cardiovascular morbidity and mortality in the oldest old: the Leiden 85-plus study.Improved risk stratification in prevention by use of a panel of selected circulating microRNAs.The transcriptomic profile of peripheral blood nuclear cells in dogs with heart failureElevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapyN-terminal pro-brain natriuretic peptide and associated factors in the general working population: a baseline survey of the Uranosaki cohort study.Biomarkers and cardiovascular risk assessment for primary prevention: an update.How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic reviewNatriuretic Peptides and Assessment of Cardiovascular Disease Risk in Asymptomatic Persons.N-terminal pro-B-type natriuretic peptide, left ventricular mass, and incident heart failure: Multi-Ethnic Study of AtherosclerosisN-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study.
P2860
Q21261433-75684590-4562-434D-B2F9-0826054D0465Q24607043-CECA4ADC-EE46-4F75-8FB8-7BFB1B4DEFD3Q24812557-7293CAAB-D893-4DBE-8BF7-A5D30D002545Q26745091-A4FEA8F6-37A2-4F52-91B0-6AAE766A1F63Q26827702-38931A8E-D027-4E8C-B58E-0371AF28A5E9Q27341873-B738F2F0-363E-4A62-A20C-0160C0CD277AQ28082833-1BCBFA7C-8F0F-49FE-97A7-74738B9ADEB8Q28083473-F2158B2C-5F72-4D69-A666-5F376BE7E087Q28572107-8244DC92-586A-45B4-9659-F368AE4AC3BEQ28602715-41B6C02C-1339-4024-9D23-3121A4C1E2DBQ28730261-A2B79E5A-1AF3-4F40-A3B9-38D40BC39C08Q29347295-A8DBDD63-384E-4C3D-8CCD-15A444D19E1DQ30245541-E1F9C36F-C5DA-4CE7-B2DA-72EA4533146AQ30418495-D2D29AF0-35DA-4557-9D42-BB4980D84438Q30453514-25A4C6D4-FDE9-4342-9AF0-BACE621B62B3Q30475719-47C4D957-80F7-4C6D-830D-8F5898E487AEQ30797742-6170D535-86BF-458A-AD00-BF5B8784503EQ31019192-3B4DB618-2C3E-4C0C-B9BB-8BBD364C4C7AQ31126960-DD6EA0D9-1B31-42CB-9A53-EA853FBB1040Q33392414-552DBE97-3665-419A-A3AC-4D5530CFB98BQ33551467-691292C8-E65A-4C51-ACF3-831E9292FFDAQ33555143-F7B8DECB-2C26-4395-BC6D-2057308FE103Q33572286-4C70FCC2-1079-45AA-9C33-ED3B7A0ABC7DQ33648242-E8225A8F-039B-485C-824F-C18F616506C5Q33671233-587AC169-E3AF-412D-9D35-D3CC522861C8Q33713288-D0EA0BBA-934E-40DA-A9F7-2123E37DB5ADQ33715302-7CEF8AAF-C18B-47C6-846F-794C23379F87Q33733517-38499A16-2619-4896-98AC-865463822C9AQ33769784-68246CD5-FA9D-4FBC-A492-6DA27F837DEFQ33771715-4C45C38B-9C15-45DD-8554-F053286C0665Q33848664-AF162763-1F85-4133-9319-0031611735DDQ33866958-6779A7EF-CA1F-4B7C-91F0-264E490CAB96Q33883059-AADA19B7-6FF2-4F85-9E65-68C8A1AFD39CQ33909833-206C1361-2213-44EB-8B72-7194B5E83B8BQ33918896-ED5B6BB0-5D1E-47D3-AD63-BA599FF8493CQ33927398-9B129EF9-A446-4343-96E0-1DD8187CB01DQ33932889-5CC579B3-F847-41DC-8FA9-FFD911BDCC05Q33948944-6C1A7C23-D80A-4181-91C4-3DC522826127Q34014190-785A2A5D-2863-414D-8E68-ADDF0A4E679EQ34041862-E5DCFA11-1E16-4C2C-BF29-9FF6ABE0E0BA
P2860
Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
@ast
Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
@en
Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
@nl
type
label
Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
@ast
Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
@en
Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
@nl
prefLabel
Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
@ast
Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
@en
Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
@nl
P2093
P50
P356
P1476
Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
@en
P2093
Daniel Levy
Eric P Leip
Thomas J Wang
Torbjorn Omland
P304
P356
10.1056/NEJMOA031994
P407
P577
2004-02-01T00:00:00Z